No Data
Everbright: Import substitution is expected to accelerate, pay attention to the rising market share of domestic surgical robots.
Everbright stated that the import substitution is expected to accelerate, paying attention to the rise in market share of domestic surgical robots.
China Securities Co.,Ltd.: It is recommended to focus on the new growth and integration opportunities in the Industry.
China Securities Co.,Ltd. remains bullish on high-quality Innovative Drugs companies in 2025 and actively focuses on cutting-edge technologies in pharmaceuticals and medical devices.
What Does The Future Hold For MicroPort NeuroScientific Corporation (HKG:2172)? These Analysts Have Been Cutting Their Estimates
On April 3, MicroPort Neuroscience (02172) spent 3.5853 million Hong Kong dollars to repurchase 0.32 million shares.
Micro Innovations in Brain Science (02172) announced that on April 3, 2025, a total of 3.5853 million Hong Kong dollars was spent to repurchase 0.32 million shares...
[Brokerage Focus]浦银 International maintains a "Buy" rating for Micro-Invasive Neuroscience (02172), expecting the company to return to its normal growth trajectory by 2026.
Jingwu Financial News |浦银国际 Research Reports indicate that Micro-invasive Neuroscience (02172) will have a revenue of 0.76 billion yuan in 2024 (+14.4% YoY), with a 3.5% year-on-year decline in revenue for 2H24, mainly due to the company's adjustment of the factory prices for mesh Brackets and spring coils as collective procurement advances; gross margin stands at 73.0% (-3.9 percentage points YoY); 2024 Net income/Adjusted net income is 0.25 billion/0.28 billion yuan (+85%/+44% YoY). Looking at the production lines, the revenue of the company's four major Business Sectors has recorded a decline in hemorrhage and access products: 1) Contribution to the company's income.
MicroPort NeuroScience (02172.HK) spent 3.12 million Hong Kong dollars to repurchase 0.271 million shares on April 2.
On April 2, Glontelligence announced that Microsurgery Neuroscience (02172.HK) repurchased 0.271 million shares for 3.12 million Hong Kong dollars.
